TY - JOUR
T1 - Optimal management of constipation associated with irritable bowel syndrome
AU - Furnari, Manuele
AU - De Bortoli, Nicola
AU - Martinucci, Irene
AU - Bodini, Giorgia
AU - Revelli, Matteo
AU - Marabotto, Elisa
AU - Moscatelli, Alessandro
AU - Del Nero, Lorenzo
AU - Savarino, Edoardo
AU - Giannini, Edoardo G.
AU - Savarino, Vincenzo
PY - 2015/4/30
Y1 - 2015/4/30
N2 - Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor–patient relationship still seems to be the key for success.
AB - Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor–patient relationship still seems to be the key for success.
KW - Functional gastrointestinal disorders
KW - IBS
KW - Laxatives
UR - http://www.scopus.com/inward/record.url?scp=84930193035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930193035&partnerID=8YFLogxK
U2 - 10.2147/TCRM.S54298
DO - 10.2147/TCRM.S54298
M3 - Article
AN - SCOPUS:84930193035
VL - 11
SP - 691
EP - 703
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
SN - 1176-6336
ER -